Measuring the intravitreal mobility of nanomedicines with single-particle tracking microscopy

Nanomedicine

Volumn 8, Issue 12, 2013, Pages 1955-1968

  Martens, Thomas F ^a   Vercauteren, Dries ^a   Forier, Katrien ^a   Deschout, Hendrik ^a   Remaut, Katrien ^a   Paesen, Rik ^b   Ameloot, Marcel ^b   Engbersen, Johan F J ^c   Demeester, Jo ^a   De Smedt, Stefaan C ^a   Braeckmans, Kevin ^a  

^a GHENT UNIVERSITY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

^c UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

diffusion; intravitreal injection; nanomedicine; nanoparticle; ocular gene therapy; polyplex; single particle tracking

Indexed keywords

NANOPARTICLE; NANOSPHERE; PLASMID DNA; POLYAMIDOAMINE; POLYSTYRENE;

ANIMAL TISSUE; ARTICLE; EXTRACELLULAR MATRIX; FLUORESCENCE MICROSCOPY; LIGHT SCATTERING; NANOMEDICINE; NONHUMAN; PRIORITY JOURNAL; VITREOUS BODY;

ANIMALS; CATTLE; DNA; INTRAVITREAL INJECTIONS; MICROSCOPY, FLUORESCENCE; NANOMEDICINE; NANOPARTICLES; PLASMIDS; POLYETHYLENE GLYCOLS; VITREOUS BODY;

EID: 84889566066     PISSN: 17435889     EISSN: 17486963     Source Type: Journal    
DOI: 10.2217/nnm.12.202     Document Type: Article

References (61)

1. Phelan JK, Bok D. A brief review of retinitis pigmentosa and the identified retinitis pigmentosa genes. Mol. Vis. 6, 116-124 (2000
2. Colella P, Cotugno G, Auricchio A. Ocular gene therapy: Current progress and future prospects. Trends Mol. Med. 15(1), 23-31 (2009
3. den Hollander AI, Roepman R, Koenekoop RK, Cremers FP. Leber congenital amaurosis: Genes, proteins and disease mechanisms. Prog. Retin. Eye Res. 27(4), 391-419 (2008
4. Campochiaro PA. Gene transfer for neovascular age-related macular degeneration. Hum. Gene Ther. 22(5), 523-529 (2011
5. Bainbridge JW, Tan MH, Ali RR. Gene therapy progress and prospects: The eye. Gene Ther. 13(16), 1191-1197 (2006 (Pubitemid 44184712)
6. Liu MM, Tuo J, Chan CC. Republished review: Gene therapy for ocular diseases. Postgrad. Med. J. 87(1029), 487-495 (2011
7. Patil SD, Rhodes DG, Burgess DJ. DNA based therapeutics and DNA delivery systems: A comprehensive review. AAPS J. 7(1), E61-E77 (2005 (Pubitemid 41554297)
8. Del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Discov. Today 13(3-4), 135-143 (2008
9. Barar J, Javadzadeh AR, Omidi Y. Ocular novel drug delivery: Impacts of membranes and barriers. Exp. Opin. Drug Del. 5(5), 567-581 (2008 (Pubitemid 351877434)
10. Vandervoort J, Ludwig A. Ocular drug delivery: Nanomedicine applications. Nanomedicine (Lond.) 2(1), 11-21 (2007 (Pubitemid 46845773)
11. Bochot A, Mashhour B, Puisieux F, Couvreur P, Fattal E. Comparison of the ocular distribution of a model oligonucleotide after topical instillation in rabbits of conventional and new dosage forms. J. Drug Target. 6(4), 309-313 (1998 (Pubitemid 29033975)
12. Kachi S, Oshima Y, Esumi N et al. Nonviral ocular gene transfer. Gene Ther. 12(10), 843-851 (2005 (Pubitemid 40753976)
13. Johnson CJ, Berglin L, Chrenek MA, Redmond TM, Boatright JH, Nickerson JM. Technical brief: Subretinal injection and electroporation into adult mouse eyes. Mol. Vis. 14(258-259), 2211-2226 (2008
14. Kachi S, Esumi N, Zack DJ, Campochiaro PA. Sustained expression after nonviral ocular gene transfer using mammalian promoters. Gene Ther. 13(9), 798-804 (2006
15. Bloquel C, Bourges JL, Touchard E, Berdugo M, BenEzra D, Behar-Cohen F. Nonviral ocular gene therapy: Potential ocular therapeutic avenues. Adv. Drug Deliv. Rev. 58(11), 1224-1242 (2006 (Pubitemid 44794428)
16. Fisher SK, Lewis GP, Linberg KA, Verardo MR. Cellular remodeling in mammalian retina: Results from studies of experimental retinal detachment. Prog. Retin. Eye Res. 24(3), 395-431 (2005 (Pubitemid 40238670)
17. Rodrigues EB, Farah ME, Maia M et al. Therapeutic monoclonal antibodies in ophthalmology. Prog. Retin. Eye Res. 28(2), 117-144 (2009
18. Fattal E, Bochot A. Ocular delivery of nucleic acids: Antisense oligonucleotides, aptamers and siRNA. Adv. Drug Deliv. Rev. 58(11), 1203-1223 (2006
19. Conley SM, Naash MI. Nanoparticles for retinal gene therapy. Prog. Retin. Eye Res. 29(5), 376-397 (2010
20. Naik R, Mukhopadhyay A, Ganguli M. Gene delivery to the retina: Focus on nonviral approaches. Drug Discov. Today 14(5-6), 306-315 (2009
21. Sakamoto T, Ikeda Y, Yonemitsu Y. Gene targeting to the retina. Adv. Drug Deliv. Rev. 52(1), 93-102 (2001 (Pubitemid 32973641)
22. Maguire AM, High KA, Auricchio A et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A Phase I dose-escalation trial. Lancet 374(9701), 1597-1605 (2009
23. Hennig AK, Ogilvie JM, Ohlemiller KK, Timmers AM, Hauswirth WW, Sands MS. AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice. Mol. Ther. 10(1), 106-116 (2004 (Pubitemid 38878153)
24. Derksen TA, Sauter SL, Davidson BL. Feline immunodeficiency virus vectors. Gene transfer to mouse retina following intravitreal injection. J. Gene Med. 4(5), 463-469 (2002 (Pubitemid 40268371)
25. Petrs-Silva H, Dinculescu A, Li Q et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol. Ther. 19(2), 293-301 (2011
26. Kumar-Singh R. Barriers for retinal gene therapy: Separating fact from fiction. Vision Res. 48(16), 1671-1680 (2008
27. Thomas CE, Ehrhardt A, Kay MA. Progress and problems with the use of viral vectors for gene therapy. Nat. Rev. Genet. 4(5), 346-358 (2003 (Pubitemid 36538359)
28. Zinkernagel MS, McMenamin PG, Forrester JV, Degli-Esposti MA. T cell responses in experimental viral retinitis: Mechanisms, peculiarities and implications for gene therapy with viral vectors. Prog. Retin. Eye Res. 30(4), 275-284 (2011
29. Li Q, Miller R, Han PY et al. Intraocular route of AAV2 vector administration defines humoral immune response and therapeutic potential. Mol. Vis. 14, 1760-1769 (2008
30. Provost N, Le Meur G, Weber M et al. Biodistribution of rAAV vectors following intraocular administration: Evidence for the presence and persistence of vector DNA in the optic nerve and in the brain. Mol. Ther. 11(2), 275-283 (2005
31. Farjo R, Skaggs J, Quiambao AB, Cooper MJ, Naash MI. Efficient nonviral ocular gene transfer with compacted DNA nanoparticles. PLoS ONE 1, e38 (2006
32. Cai X, Conley S, Naash M. Nanoparticle applications in ocular gene therapy. Vision Res. 48(3), 319-324 (2008 (Pubitemid 351179511)
33. Koirala A, Makkia RS, Cooper MJ, Naash MI. Nanoparticle-mediated gene transfer specific to retinal pigment epithelial cells. Biomaterials 32(35), 9483-9493 (2011
34. Tamboli V, Mishra GP, Mitra AK. Polymeric vectors for ocular gene delivery. Ther. Deliv. 2(4), 523-536 (2011
35. Bishop PN. Structural macromolecules and supramolecular organization of the vitreous gel. Prog. Retin. Eye Res. 19(3), 323-344 (2000 (Pubitemid 30122726)
36. Sakurai E, Ozeki H, Kunou N, Ogura Y. Effect of particle size of polymeric nanospheres on intravitreal kinetics. Ophthalmic Res. 33(1), 31-36 (2001
37. Pitkanen L, Ruponen M, Nieminen J, Urtti A. Vitreous is a barrier in nonviral gene transfer by cationic lipids and polymers. Pharm. Res. 20(4), 576-583 (2003 (Pubitemid 36438900)
38. Peeters L, Sanders NN, Braeckmans K et al. Vitreous: A barrier to nonviral ocular gene therapy. Invest. Ophth. Vis. Sci. 46(10), 3553-3561 (2005 (Pubitemid 44264656)
39. Kim H, Robinson SB, Csaky KG. Investigating the movement of intravitreal human serum albumin nanoparticles in the vitreous and retina. Pharm. Res. 26(2), 329-337 (2009
40. Koo H, Moon H, Han H et al. The movement of self-Assembled amphiphilic polymeric nanoparticles in the vitreous and retina after intravitreal injection. Biomaterials 33(12), 3485-3493 (2012
41. Braeckmans K, Vercauteren D, Demeester J, de Smed SC. Single particle tracking. In: Nanoscopy and Multidimensional Optical Fluorescence Microscopy. Diaspro A (Ed.). Taylor and Francis, NY, USA, 5.1-5.17 (2010
42. Lai SK, Hanes J. Real-Time multiple particle tracking of gene nanocarriers in complex biological environments. Methods Mol. Biol. 434, 81-97 (2008
43. Braeckmans K, Buyens K, Bouquet W et al. Sizing nanomatter in biological fluids by fluorescence single particle tracking. Nano. Lett. 10(11), 4435-4442 (2010
44. Naeye B, Deschout H, Roding M et al. Hemocompatibility of siRNA loaded dextran nanogels. Biomaterials 32(34), 9120-9127 (2011
45. Lin C, Zhong ZY, Lok MC et al. Novel bioreducible poly(amido amine)s for highly efficient gene delivery. Bioconjugate Chem. 18(1), 138-145 (2007 (Pubitemid 46146003)
46. Vercauteren D, Piest M, van der Aa LJ et al. Flotillin-dependent endocytosis and a phagocytosis-like mechanism for cellular internalization of disulfide-based poly(amido amine)/DNA polyplexes. Biomaterials 32(11), 3072-3084 (2011
47. Symens N, Walczak R, Demeester J, Mattaj I, De Smedt SC, Remaut K. Nuclear inclusion of nontargeted and chromatin-Targeted polystyrene beads and plasmid DNA containing nanoparticles. Mol. Pharm. 8(5), 1757-1766 (2011
48. Saxton MJ, Jacobson K. Single-particle tracking: Applications to membrane dynamics. Ann. Rev. Biophys. Biomol. Struct. 26, 373-399 (1997 (Pubitemid 27255378)
49. Rodrigues EB, Grumann A, Penha FM et al. Effect of needle type and injection technique on pain level and vitreal reflux in intravitreal injection. J. Ocul. Pharmacol. Ther. 27(2), 197-203 (2011
50. Ruponen M, Yla-Herttuala S, Urtti A. Interactions of polymeric and liposomal gene delivery systems with extracellular glycosaminoglycans: Physicochemical and transfection studies. Biochim. Biophys. Acta 1415(2), 331-341 (1999 (Pubitemid 29065298)
51. Bos KJ, Holmes DF, Meadows RS, Kadler KE, McLeod D, Bishop PN. Collagen fibril organization in mammalian vitreous by freeze etch/rotary shadowing electron microscopy. Micron 32(3), 301-306 (2001
52. Wang Y, Xu Z, Zhang R, Li W, Yang L, Hu Q. A facile approach to construct hyaluronic acid shielding polyplexes with improved stability and reduced cytotoxicity. Colloids Surf. B Biointerfaces 84(1), 259-266 (2011
53. Nickerson CS, Park J, Kornfield JA, Karageozian H. Rheological properties of the vitreous and the role of hyaluronic acid. J. Biomech. 41(9), 1840-1846 (2008
54. Sanders NN, Peeters L, Lentacker I, Demeester J, De Smedt SC. Wanted and unwanted properties of surface PEGylated nucleic acid nanoparticles in ocular gene transfer. J. Control. Release 122(3), 226-235 (2007 (Pubitemid 47404669)
55. Gomes dos Santos AL, Bochot A, Tsapis N et al. Oligonucleotide- polyethylenimine complexes targeting retinal cells: Structural analysis and application to anti-TGF-b-2 therapy. Pharm. Res. 23(4), 770-781 (2006
56. Xu J, Heys JJ, Barocas VH, Randolph TW. Permeability and diffusion in vitreous humor: Implications for drug delivery. Pharm. Res. 17(6), 664-669 (2000 (Pubitemid 30670630)
57. Stay MS, Xu J, Randolph TW, Barocas VH. Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor. Pharm. Res. 20(1), 96-102 (2003 (Pubitemid 36152923)
58. Park J, Bungay PM, Lutz RJ et al. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J. Control. Release 105(3), 279-295 (2005 (Pubitemid 40941993)
59. Los LI, van der Worp RJ, van Luyn MJ, Hooymans JM. Age-related liquefaction of the human vitreous body: LM and TEM evaluation of the role of proteoglycans and collagen. Invest. Ophth. Vis. Sci. 44(7), 2828-2833 (2003 (Pubitemid 36759741)
60. Bourges JL, Gautier SE, Delie F et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest. Ophth. Vis. Sci. 44(8), 3562-3569 (2003 (Pubitemid 36909796)
61. Bejjani RA, BenEzra D, Cohen H et al. Nanoparticles for gene delivery to retinal pigment epithelial cells. Mol. Vis. 11, 124-132 (2005 (Pubitemid 41358300)